- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04642742
Impact of a Chewable Plant Sterol Supplement on LDL-C in A Real-World Setting
November 21, 2020 updated by: Piper Biosciences, Inc.
The purpose of this study is to measure the effectiveness of a twice daily plant sterol supplement, which is in a gummy format and packaged with health insights, in reducing LDL-C cholesterol in a real word setting.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
While the safety and benefits of plant sterol supplements have been established and are incorporated into many lipid lowering guidelines, there have been few prior studies of plant sterol chewables in gummy format among real world subjects.
In this study, we aim to measure the LDL-C reducing impact of regular plant sterol supplementation in a real world setting.
Study Type
Observational
Enrollment (Anticipated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Altos, California, United States, 94024
- Piper Biosciences, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Purchasers of OTC plant sterol product who have used the plant sterol product for at least 10 weeks
Description
Inclusion Criteria:
- Subject is an adult ≥18 years of age who continuously used the sponsor's product for at least 10 weeks prior to the Follow-on Lipid Test
- Baseline Lipid Test conducted within past 2 years
- If smoker, smoking status or frequency has not changed between two lipid test dates
- Subject understands the study procedures and signs forms documenting informed consent
Exclusion Criteria:
- Subject was taking a prescription cholesterol-lowering medication or taking dietary supplements for cholesterol-lowering such as red yeast rice, niacin or omega-3 fatty acid supplements at the time of either lipid test
- Subject does not read English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Plant sterol chewable
|
Chewable plant sterol (gummy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
% change in LDL-C from baseline
Time Frame: >10 weeks
|
>10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 25, 2020
Primary Completion (Anticipated)
November 11, 2021
Study Completion (Anticipated)
November 11, 2021
Study Registration Dates
First Submitted
November 10, 2020
First Submitted That Met QC Criteria
November 21, 2020
First Posted (Actual)
November 24, 2020
Study Record Updates
Last Update Posted (Actual)
November 24, 2020
Last Update Submitted That Met QC Criteria
November 21, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20209v4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingPrimary Hyperlipidemia
-
Gan & Lee Pharmaceuticals.RecruitingPrimary HyperlipidemiaChina
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Chengdu Diao Jiuhong Pharmaceutical FactoryRecruiting
-
Washington University School of MedicineRecruitingHypercholesterolemia and HyperlipidemiaUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingHypercholesterolemia and HyperlipidemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Dr. Md. Alimur RezaRecruitingHyperlipidemia (E.G., Hypercholesterolemia)Bangladesh
Clinical Trials on Chewable plant sterol
-
Maastricht University Medical CenterNot yet recruiting
-
University of HelsinkiUniversity of Eastern FinlandCompleted
-
Stanford UniversityPiper Biosciences, Inc.CompletedCardiovascular Risk FactorUnited States
-
University of ManitobaCompletedHyperlipidemiaUnited States, Canada
-
University Hospital, SaarlandUnknown
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
French Cardiology SocietyFondation Coeur et ArtèresWithdrawnHypercholesterolemiaFrance
-
Maastricht University Medical CenterUnilever R&DCompleted
-
Maastricht University Medical CenterUnilever R&D; Raisio Group; BASFUnknownNon-Alcoholic Fatty Liver DiseaseNetherlands
-
Inner Mongolia Yili Industrial Group Co., LtdCompletedHypercholesterolemiaChina